Rapid Dose Therapeutics (XCNQ:DOSE) Buyback Yield % : -6.25 (As of Apr. 30, 2025)

View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Rapid Dose Therapeutics's current buyback yield was -6.25%.

Rapid Dose Therapeutics Buyback Yield % Historical Data

The historical data trend for Rapid Dose Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Buyback Yield % Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Buyback Yield %

Get a 7-Day Free Trial

-3.36

-5.31

-1.63

-5.84

Rapid Dose Therapeutics Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Buyback Yield %	Get a 7-Day Free Trial															-	-5.84	-2.16	-4.61	-3.80

Competitive Comparison of Rapid Dose Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Rapid Dose Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Rapid Dose Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Rapid Dose Therapeutics's Buyback Yield for the fiscal year that ended in Feb. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	1.205)	/	20.61675
	=	-5.84%

Rapid Dose Therapeutics's annualized Buyback Yield for the quarter that ended in Nov. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	1.365)		/	35.96376
	=	-3.80%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Rapid Dose Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

RDTCF:USA

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

https://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Executives

Mark Upsdell	Director
Brian Howlett	Director

Rapid Dose Therapeutics Headlines

No Headlines